Type 3 neovascularization is considered to originate within the retina with subsequent expansion of the neovascular network into the subretinal space. Choroidal circulatory disturbances seem to have a role in Type 3 neovascularization development, but the exact pathophysiology is still under debate. Although eyes with Type 3 neovascularization usually have thinner choroid compared to normal eyes, the increased choroidal thickness associated with Type 3 neovascularization may be a prognostic factor for its recurrence. This case report documents stage 1 Type 3 neovascularization with dilated choroid showing poor response to anti-vascular endothelial growth factor therapy, thus suggesting an active role of choroid in Type 3 lesions.

Stage 1 type 3 neovascularization with choroidal dilation unresponsive to anti-VEGF treatment / S. Vujosevic, F. Martini, E. Midena. - In: OPHTHALMIC SURGERY, LASERS & IMAGING RETINA. - ISSN 2325-8160. - 47:10(2016 Oct), pp. 956-959. [10.3928/23258160-20161004-10]

Stage 1 type 3 neovascularization with choroidal dilation unresponsive to anti-VEGF treatment

S. Vujosevic
Primo
;
2016

Abstract

Type 3 neovascularization is considered to originate within the retina with subsequent expansion of the neovascular network into the subretinal space. Choroidal circulatory disturbances seem to have a role in Type 3 neovascularization development, but the exact pathophysiology is still under debate. Although eyes with Type 3 neovascularization usually have thinner choroid compared to normal eyes, the increased choroidal thickness associated with Type 3 neovascularization may be a prognostic factor for its recurrence. This case report documents stage 1 Type 3 neovascularization with dilated choroid showing poor response to anti-vascular endothelial growth factor therapy, thus suggesting an active role of choroid in Type 3 lesions.
Aged; Angiogenesis Inhibitors; Bevacizumab; Choroid; Choroidal Neovascularization; Dilatation, Pathologic; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Humans; Male; Tomography, Optical Coherence; Treatment Failure; Vascular Endothelial Growth Factor A
Settore MED/30 - Malattie Apparato Visivo
Article (author)
File in questo prodotto:
File Dimensione Formato  
OSLIcase-reportRAP2016.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 211.61 kB
Formato Adobe PDF
211.61 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/884450
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact